Anika Therapeutics (ANIK) Shares Outstanding (2010 - 2026)

Anika Therapeutics (ANIK) has reported Shares Outstanding (Entity) for 17 consecutive years, with $13.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) fell 7.18% year-over-year to $13.4 million in Q2 2026; TTM through Jun 2026 was $13.4 million, a 7.18% decrease from a year earlier, with the FY2025 full-year figure at $13.9 million, down 3.66% from the prior year.
• Shares Outstanding (Entity) was $13.4 million for Q2 2026 at Anika Therapeutics, roughly flat from $13.4 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $14.8 million in Q2 2024 and troughed at $13.4 million in Q1 2026.
• A 5-year average of $14.4 million and a median of $14.6 million in 2022 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) increased 1.54% in 2023 and decreased 7.18% in 2026, its largest moves.
• Over 5 years, Shares Outstanding (Entity) stood at $14.6 million in 2022, then gained by 0.24% to $14.7 million in 2023, then fell by 1.66% to $14.4 million in 2024, then slipped by 3.66% to $13.9 million in 2025, then decreased by 3.64% to $13.4 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $13.4 million (Q2 2026), $13.4 million (Q1 2026), and $13.9 million (Q4 2025), per Business Quant data.